| Sign In to gain access to subscriptions and/or personal tools. |
Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers
1 Department of Medicine, Johns Hopkins University, Baltimore, Maryland,
USA
* To whom correspondence should be addressed.
Abstract The objective of this study is to determine the safety, tolerability and abuse liability of single intravenous (i.v.) doses of lisdexamfetamine dimesylate (LDX) and immediate-release d-amphetamine sulphate in adult stimulant abusers compared with placebo. Adult substance abusers were enrolled in this phase I, randomized, single-centre, double-blind study. An initial cohort of three subjects was enrolled to assess safety followed by a primary cohort that consisted of nine subjects. Single i.v. doses of LDX (25 or 50 mg), immediate-release d-amphetamine sulphate (10 or 20 mg) or placebo were administered at a minimum of 48-h intervals in a single-dose, three-way crossover design. 20 mg of d-amphetamine showed significantly increased abuse-related liking scores compared with placebo (P < 0.05), whereas the liking effects of 50 mg LDX did not significantly differ from placebo. The mean Cmax of d-amphetamine was 38.9 ± 8.1 and 105 ± 91.4 ng/ml after the administration of 50 mg LDX and 20 mg d-amphetamine respectively. The mean Tmax of d-amphetamine was 2.51 h after the administration of 50 mg LDX and 0.82 h after the administration of 20 mg d-amphetamine. LDX was well tolerated in this population. In contrast to d-amphetamine, LDX administered intravenously did not produce significant subjective abuse-related liking scores at assessed doses. Key Words: abuse, ADHD, LDX, stimulant, Vyvanse
First published on July 17, 2008, doi:10.1177/0269881108093841 This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
